Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 102Carcinoid Tumor 22Neoplasms 16Neoplasm Metastasis 10Gastro-enteropancreatic neuroendocrine tumor 10Carcinoma, Neuroendocrine 9Adenoma, Islet Cell 9Pancreatic Neoplasms 7Carcinoma 7Pheochromocytoma 6Paraganglioma 6Neuroblastoma 6Colorectal Neoplasms 6Carcinoma, Islet Cell 6Somatostatinoma 5Gastrointestinal Neoplasms 5Vipoma 4Small Cell Lung Carcinoma 4Serotonin Syndrome 4Neuroectodermal Tumors, Primitive 4Melanoma 4Medulloblastoma 4Lung Neoplasms 4Intestinal Neoplasms 4Gastrinoma 4Carcinoma, Non-Small-Cell Lung 4Adenocarcinoma 4Prostatic Neoplasms 3Neuroectodermal Tumors 3Neoplasms, Nerve Tissue 3

Interventions

gallium Ga 68 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × von Hippel-Lindau Disease × NET × Clear all
NCT01967537 2019-11-19

Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
341 enrolled 14 charts
EndocrineNET

von Hippel-Lindau Disease, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡